Cargando…
165 Early Versus Delayed Treatment of Swelling Attacks with Icatibant, a Bradykinin 2 Receptor Antagonist in Patients With Hereditary Angioedema due to C1-INH Deficiency
BACKGROUND: To compare the efficacy of icatibant in early versus late treated attacks of hereditary angioedema. METHODS: Thirty-one patients received 30 mg icatibant subcutaneously at various times for 121 swelling attacks. The time periods between onset of attacks and icatibant injection, icatibant...
Autores principales: | Bork, Konrad, Hardt, Jochen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization Journal
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513132/ http://dx.doi.org/10.1097/01.WOX.0000411922.50578.13 |
Ejemplares similares
-
164 Treatment of Acquired Angioedema with the Bradykinin Receptor Antagonist Icatibant
por: Siani, Maria Concetta, et al.
Publicado: (2012) -
454 Efficacy of Icatibant Versus Fresh Frozen Plasma for Attacks of Hereditary Angioedema: Analysis of Indivudual Symptoms by Attack Site
por: Lara, Alicia, et al.
Publicado: (2012) -
83 Hereditary Angioedema and Normal C1-Inhibitor (HAE TYPE III): A Novel Mutation in the Coagulation Factor 12 Gene
por: Bork, Konrad, et al.
Publicado: (2012) -
455 Characterization of the Factors Triggering an Edematous Attack in Hereditary Angioedema
por: Zotter, Zsuzsanna, et al.
Publicado: (2012) -
85 Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks
por: Reshef, Avner, et al.
Publicado: (2012)